Elicio Therapeutics (NASDAQ:ELTX) Announces Earnings Results, Beats Expectations By $0.14 EPS

Elicio Therapeutics (NASDAQ:ELTX) posted its earnings results on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.14, FiscalAI reports.

Elicio Therapeutics Stock Performance

NASDAQ ELTX traded up $0.11 on Friday, reaching $1.51. The stock had a trading volume of 756,123 shares, compared to its average volume of 285,067. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.77 and a quick ratio of 2.77. The company has a market cap of $40.91 million, a P/E ratio of -0.81 and a beta of 1.64. The firm has a fifty day moving average of $1.91 and a two-hundred day moving average of $6.58. Elicio Therapeutics has a 1-year low of $1.25 and a 1-year high of $16.00.

Wall Street Analyst Weigh In

ELTX has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Elicio Therapeutics in a research report on Tuesday, October 27th. HC Wainwright reissued a “buy” rating on shares of Elicio Therapeutics in a research note on Tuesday, August 18th. B. Riley Financial lowered their target price on shares of Elicio Therapeutics to $8.00 and set a “buy” rating on the stock in a report on Thursday, September 24th. Finally, Wall Street Zen raised shares of Elicio Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

About Elicio Therapeutics

Elicio Therapeutics, Inc (NASDAQ: ELTX) is a clinical-stage biotechnology company developing immunotherapies designed to activate the immune system against cancer. The company’s approach is based on its proprietary Amphiphile technology, which is intended to direct vaccine components and immune-stimulating agents to lymph nodes, where important immune responses are initiated.

Elicio’s lead program is ELI-002, a therapeutic cancer vaccine being developed for patients with tumors containing mutations in the KRAS gene.